-
-
-
-
-
-
-
Legend Biotech Corp. (LEGN) PT Lowered to $59 at RBC Capital
-
-
-
-
-
-
-
RBC Capital on Legend Biotech Corp. (LEGN): 'We remain buyers'
-
-
-
-
-
-
-
RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
-
-
-
-
-
-
Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN) After FDA Draft Guidance
-
-
-
-
-
-
-
Breakthrough Properties partners with Eli Lilly for Philadelphia lab space
-
-
-
-
-
-
-
Cantor Fitzgerald Assumes Legend Biotech Corp. (LEGN) at Overweight
-
456,082 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

